ImmunityBio Files 8-K on Director/Officer Changes & Voting Matters
Ticker: IBRX · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, leadership-change, filing
Related Tickers: IBIO
TL;DR
IBIO filed an 8-K detailing leadership changes and upcoming shareholder votes.
AI Summary
ImmunityBio, Inc. filed an 8-K on June 20, 2025, reporting events as of June 18, 2025. The filing covers the departure of directors, election of directors, appointment of officers, and compensatory arrangements. It also includes the submission of matters to a vote of security holders and financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and governance, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with votes on company matters, can signal shifts in strategy or internal dynamics that may affect the company's future performance.
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- June 18, 2025 (date) — Earliest event reported
- June 20, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 3530 John Hopkins Court, San Diego, California 92121 (address) — Business and mail address
FAQ
What specific items were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
Who are the departing directors or officers?
The filing states that there was a departure of directors or certain officers, but the names of these individuals are not specified in the provided text.
Who are the newly elected directors or appointed officers?
The filing mentions the election of directors and appointment of certain officers, but their names are not detailed in the excerpt.
What is the nature of the compensatory arrangements for certain officers?
The filing notes that there are compensatory arrangements for certain officers, but the specifics of these arrangements are not elaborated upon in the provided text.
What financial statements and exhibits are included with this filing?
The filing indicates that financial statements and exhibits are included, but their content is not described in the excerpt.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding ImmunityBio, Inc. (IBRX).